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Abstract: Polycystic ovary syndrome (PCOS) is a common lifestyle-related endocrinopathy in 
women of reproductive age and is associated with several mental health problems. We examined 
the genotypic distributions of IRS-1 Gly972Arg and CYP11B2 -344T/C, which were previously 
described as influencing PCOS, and assayed the serum levels of interleukin-6 (IL-6) and tumor 
necrosis factor-alpha (TNF-α), in a set of female patients with borderline personality disorder 
(BPD) with comorbid major depressive disorder (MDD) (n = 50) and age-matched control 
subjects (n = 100), to investigate the predisposition for BPD with MDD. The results showed 
that the patients were more frequently IRS-1 972Arg variant allele carriers (P = 0.013; OR 
6.68; 95% CI = 1.30–34.43) and homozygous for the CYP11B2 -344C variant allele (P = 0.022; 
OR = 3.32; 95% CI = 1.18–9.35) than the control subjects. The IL-6 level was significantly 
higher in the patients than in the controls (P , 0.0001). There was no significant difference 
in the serum TNF-α level between patients with BPD with MDD and the healthy comparison 
group (P = 0.5273). In conclusion, the predisposition for BPD with MDD is associated with 
that for PCOS, in the female Japanese population. An elevated serum IL-6 level is considered 
to be a possible biomarker of BPD with MDD.
Keywords: borderline personality disorder, depression, polycystic ovary syndrome, genetic 
polymorphism, insulin resistance
Introduction
Borderline personality disorder (BPD) is a serious public health problem predominant 
in women, and is characterized by interpersonal stress, affective instability,   impulsivity, 
stress-related dissociation, repeated self-mutational behavior, and chronic suicidal 
tendencies.1 BPD affects 1%–2% of the general population, and 41%–83% of patients 
with BPD report a history of major depressive disorder (MDD).1 The etiology of BPD 
is not yet clear, and relatively little data exist regarding biological causes compared 
with psychosocial ones, such as traumatic life events and the family environment in 
their childhood.2,3 Biological causes underlying BPD have been investigated mainly 
from the viewpoint of monoamine neurotransmission,4–6 although some metabolic and 
endocrinal disturbances also have been assessed to investigate the biological   etiology 
involved. Dysregulation of the hypothalamic-pituitary axis, elevations in levels of pro-
inflammatory cytokines (interleukin-6 [IL-6] and tumor necrosis factor-alpha [TNF-α]), 
cortisol, and cortisol-dehydroepiandrosterone ratio, low bone mineral density, reduced 
insulin sensitivity, and increased visceral fat deposition have been suggested as   possible Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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contributing etiological factors among female patients with 
BPD with MDD.7–10 There is also some support for a psycho-
social cause of BPD with MDD;   specifically, chronic family 
stress in childhood has been reported to contribute to adult 
metabolic function and atypical activity of the hypothalamic-
pituitary axis.11 However, previous reports also suggest that 
some forms of BPD with MDD are life-style related immune-
endocrine disorders.7–10
Polycystic ovary syndrome (PCOS) is a common endo-
crinopathy affecting up to 10% of women of reproductive 
age. PCOS is characterized by polycystic ovaries demon-
strable by ultrasound, chronic anovulation, and reduced 
fertility. Several metabolic and endocrinal abnormalities 
such as a rapid luteinizing hormone pulse frequency, insulin 
resistance, hyperandrogenemia, and elevated levels of serum 
cytokines maintain the PCOS status.12,13 Above all, insulin 
resistance has been considered to be the most important 
etiology of the reproductive and metabolic abnormalities in 
PCOS.14   Accordingly, PCOS is a lifestyle-related endocrine 
disorder. PCOS has also been reported to be associated with 
several mental health problems such as depressive disorder, 
bipolar disorder, anxiety disorder, posttraumatic stress dis-
order, eating disorder, and female-to-male transsexuality.15–18 
However, there is no consensus on the criteria for the diagno-
sis of PCOS. Most clinicians and researchers from the USA 
and from Southern Europe use the criteria derived from the 
conference held at the National Institute of Child Health 
and Human Development (NICHD) in 1990 such as clinical 
and/or biochemical hyperandrogenism, menstrual dysfunc-
tion, and exclusion of specific etiologies.19   According to these 
criteria, the presence of polycystic ovaries on ultrasound 
examination is not needed for the diagnosis. To diagnose 
as PCOS strictly is not easy even for specialists in the field 
of gynecology.
Our main a priori hypothesis was that the predisposition 
for BPD with MDD is associated with that for PCOS. The 
genetic correlates of BPD have been tested with regard 
to central nervous system monoamine transporters or 
receptors.20–23 However, the results are not yet definitive. 
Among the large number of genetic variants found in asso-
ciation with PCOS,24 insulin receptor substrate-1 (IRS-1) 
Gly972Arg and aldosterone synthetase (CYP11B2) -344T/C 
have been reported to influence PCOS in East-Asian 
populations.25,26 In order to investigate the predisposition 
to BPD with MDD, we evaluated its possible association 
with these two genomic variants, and assessed the influence 
of this predisposition on the serum concentrations of IL-6 
and TNF-α.
Material and methods
subjects
A total of 50 Japanese female patients suffering from BPD 
with MDD (age, 27.4 ± 4.8 years [mean ± SD; range, 
19–40 years]) participated. All met the DSM-IV diagnostic 
criteria for BPD with current or lifetime major depressive 
episode, and had been consecutively treated at Tokyo Jikei 
University Hospital, Iwate Medical University Hospital, and 
Mizusawa General Hospital. Nineteen (age, 27.2 ± 5.0 years 
[mean ± SD; range, 20–35 years]) of these 50 patients had 
a current major depressive episode, and the remaining 31 
(age, 27.5 ± 4.7 years [mean ± SD; range, 19–40 years]) 
had a lifetime history of major depressive disorder but no 
current major depressive episode. One hundred age-matched 
mentally healthy Japanese women (age, 27.6 ± 4.8 years 
[mean ± SD; range, 20–40 years]) were recruited as the 
comparison group.
Diagnoses in the patient group and exclusion of psychi-
atric disorders in the comparison group were determined 
by using the Japanese versions of the Structured Clinical 
Interview for DSM-IV (SCID) and the SCID for Personality 
  Disorders. Patients with current or lifetime anorexia nervosa 
and   schizophrenia, current oligophrenia, pregnancy, estrogen 
  deficiency, amenorrhea, infectious or auto-inflammatory 
disease, and aged 17 years or younger were excluded. All 
interviews were carried out by six trained and experienced 
clinicians.
The Ethics Committee on Genetics at each participating 
institution approved the present study, and the investigation 
was performed in accordance with the guidelines of the Dec-
laration of Helsinki. Written informed consent was obtained 
from all participants before personal data and blood samples 
were collected.
genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes using the NucleoMag 96 Blood (Macherey–Nagel, 
Düren, Germany) with the Biomek 3000 Laboratory 
Automation System (Beckman Coulter, Fullerton, CA) 
in accordance with the manufacturers’ instructions. Two 
  single-nucleotide polymorphisms (SNPs), IRS-1 Gly972Arg 
(rs1801278) and CYP11B2 -344T/C (rs1799998), which 
had been reported to influence PCOS in East-Asian 
populations,23,24 were selected.
Each SNP was genotyped by TaqMan® SNP Genotyping 
Assays (Applied Biosystems, Foster City, CA) using Real-
Time allelic discrimination on an ABI 7300 Real-Time poly-
merase chain reaction (PCR) System (Applied Biosystems, Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Foster City, CA). Briefly, a fluorogenic probe consisting of 
an oligonucleotide labeled with both a fluorescent reporter 
dye and a quencher dye was included in a typical PCR. 
  Amplification of the probe-specific product caused cleavage of 
the probe, generating an increase in reporter fluorescence. By 
using two different reporter dyes (5-carboxyfluorescein [FAM] 
or VIC), cleavage of allele-specific probes were detectable in a 
single PCR. The reaction mixture contained 1 µL of genomic 
DNA, 0.625 µL of 40× SNP Genotyping Assay Mix (Applied 
Biosystems, Foster City, CA), 12.5 µL of TaqMan® Universal 
PCR Master Mix, No AmpErase® UNG (Applied Biosystems, 
Foster City, CA), and 10.875 µL of distilled water in a total 
volume of 25 µL. A negative control (no-template control) 
was included in every assay. The amplification protocol was 
provided by the manufacturer and entailed an initial step at 
50°C for 2 minutes and then 95°C for 10 minutes, followed 
by 40 cycles of denaturation at 92°C for 15 seconds and one 
annealing/extension step at 58°C for 1 minute.
cytokine assays
Blood was drawn into a serum-separator collection tube 
and centrifuged for 10 minutes at 2500 rpm: the serum was 
then removed and stored at −80°C until assay. The Bio-Plex 
Human Cytokine 2-Plex panel was used with the Bio-Plex 
Suspension Array System (Bio-Rad, Hercules, CA) to profile 
the expression of IL-6 and TNF-α. The assay was performed 
in accordance with the manufacturer’s instructions. Briefly, 
serum samples were thawed and then centrifuged at 4500 rpm 
for 3 minutes at 4°C. Serum samples were then incubated 
with micro-beads labeled with specific antibodies against 
one of the aforementioned cytokines for 30 minutes. After 
a washing step, the beads were incubated with the detection 
antibody cocktail, each antibody specific to a single cytokine. 
After another washing step, the beads were incubated with 
streptavidin-phycoerythrin for 10 minutes and washed, and 
the concentration of each cytokine was determined using 
the array reader. All samples were assayed in duplicate.
statistical analysis
Fisher’s exact probability test was used to examine the asso-
ciation between BPD with MDD and the genotypes of the 
two SNPs. Hardy–Weinberg equilibrium analyses were used 
to compare the observed and expected genotype frequencies 
using χ2-test. We also performed logistic regression analy-
sis to calculate the odds ratios (ORs) and 95% confidence 
intervals (CIs) associated with the genotypes. Bartlett’s test 
revealed that the measured serum concentrations of IL-6 and 
TNF-α in the present study population did not have a normal 
distribution. Therefore, statistical analyses of   differences in 
serum cytokine levels between participants in the BPD with 
MDD group and the healthy comparison group were per-
formed by Mann–Whitney U test, and among the two patient 
groups (BPD plus current major depressive episode and 
BPD plus lifetime major depressive episode) and the healthy 
comparison group by the Kruskal–Wallis test   followed by 
the Scheffé F-test as a post hoc test.
Differences were considered statistically significant at 
P , 0.05. All analyses were conducted using SPSS 11.0J 
for Windows (SPSS Inc, Chicago, IL).
Results
concentrations of serum cytokines  
in BPD with MDD
Concentrations of IL-6 and TNF-α were compared between 
50 Japanese women suffering from BPD with MDD and 100 
healthy controls (Table 1). Bartlett’s test revealed that both 
the serum IL-6 and TNF-α concentration in the present study 
population did not have a normal distribution.
A Mann–Whitney U test revealed that the serum IL-6 level 
was significantly higher within the sample of patients with 
BPD with MDD than within the healthy comparison group 
(P , 0.0001). Kruskal–Wallis tests demonstrated significant 
differences in serum IL-6 levels among the two patient groups 
and the healthy comparison group (P , 0.0001). The Scheffé 
F-test used as a post hoc test showed that the serum IL-6 level 
Table 1 sociodemographic data and serum cytokine levels in 50 female patients with borderline personality disorder with comorbid 
major depressive disorder and 100 comparison subjects
Group Age (years) IL-6 (pg/mL) TNF-α (pg/mL)
Mean SD Mean SD SEM Mean SD SEM
comparison group (n = 100) 27.6 4.8 0.893 1.132 0.113 1.332 2.184 0.218
Patients with borderline personality disorder with comorbid major depressive disorder
  BPD plus lifetime major depressive disorder (n = 31) 27.5 4.7 7.769* 18.10 3.251 5.184 22.06 3.961
  BPD plus current major depressive episode (n = 19) 27.2 5.0 2.432 2.688 0.617 0.989 0.858 0.197
Note: *P = 0.0004 versus the comparison group.
Abbreviations: BPD, borderline personality disorder; iL-6, interleukin 6; TNF-α, tumor necrosis factor-α; sD, standard deviation; seM, standard error of the mean.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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was significantly higher in patients with BPD plus lifetime 
major depressive episode than in the healthy comparison 
group (P = 0.0004), but there was no significant difference 
in the concentration of IL-6 between patients with BPD plus 
current major depressive episode and the healthy comparison 
group (P = 0.7595). There was also no significant difference 
in the serum concentration of IL-6 between patients with BPD 
plus current major depressive episode and those with BPD plus 
lifetime major depressive episode (P = 0.0902) (Figure 1).
There was no significant difference in the serum TNF-α 
level either between patients with BPD with MDD and the 
healthy comparison group (P = 0.5273, Mann–Whitney 
U test), or among the two patient groups and the healthy 
comparison group (P = 0.7515, Kruskal–Wallis test).
Distributions of genomic variants 
associated with PcOs
The frequencies of the IRS-1 and CYP11B2 genotypes were 
compared between 50 Japanese patients suffering from BPD 
with MDD and 100 healthy controls (Table 2). The distri-
butions of genotypes in all groups were consistent with the 
Hardy–Weinberg equilibrium. Six (12%) BPD with MDD 
patients were heterozygous for the 972Arg variant of IRS-1, 
as compared with two (2%) heterozygous variant controls. 
Eighteen (36%) BPD with MDD patients were heterozygous 
for the -344C variant of CYP11B2 and ten (20%) were 
homozygous, as compared with 44 (44%) heterozygous and 
seven (7%) homozygous variant controls. The frequency 
of the IRS-1 972Arg variant allele was significantly higher 
among women with BPD with MDD than among the controls 
(P = 0.018), and the frequency of the CYP11B2-344C variant 
allele showed a P value close to 0.1 (P = 0.118). A logistic 
regression model retained women carrying the IRS-1 972Arg 
variant allele (OR = 6.68; 95% CI = 1.30–34.43; P = 0.013) 
and homozygous for the CYP11B2 -344C variant allele 
(OR = 3.32; 95% CI = 1.18–9.35; P = 0.022) for prediction 
of BPD with MDD (Table 2).
The genotypes did not affect the serum concentration of 
IL-6 or TNF-α. (data not shown).
Discussion
The present study demonstrated that serum IL-6 levels were 
significantly higher in women with BPD with MDD than that 
in healthy controls (P , 0.0001). The level of IL-6 increases 
with increasing glucose intolerance,27 and an elevated serum 
level of IL-6 in patients suffering from BPD with MDD 
is reportedly correlated with reduced insulin sensitivity.9 
Although indices of insulin resistance were not investigated 
in the present study, we wondered whether there could be 
an association between insulin resistance and BPD with 
MDD because a previous study had observed a correlation 
between reduced insulin sensitivity and serum concentrations 
of IL-6 in patients with BPD with MDD.9 In this and other 
previous studies, it was also suggested that increased pro-
inflammatory cytokines in BPD with MDD were related to 
the presence of MDD.8–10 However, our results suggested a 
different interpretation. We observed that as compared with 
healthy controls, IL-6 levels were higher in the case of BPD 
with lifetime MDD (Figure 1) and not in BPD with current 
MDD as the above studies had found. These results suggest 
a possible association between elevation of the IL-6 level and 
personality disorder in some forms of BPD with MDD, rather 
than major depressive episode. Although elevation of the 
serum IL-6 level is a non-specific feature, it is nevertheless 
considered to be a possible biomarker of BPD with MDD.
Here, we found no significant difference in the con-
centration of TNF-α between women suffering from BPD 
with MDD and the healthy comparison group. However, 
other researchers found that TNF-α levels were increased 
in patients with BPD with MDD.8–10 Although its levels are 
reportedly increased in individuals with adiposity and/or 
insulin resistance,28,29 a considerable number of investiga-
tors have failed to observe an increased TNF-α level in 
obese, compared with lean, individuals.30–32 Also, it has been 
reported that the activity of the TNF-α system is reflected by 
the levels of soluble TNF-α receptors rather than by TNF-α 
expression.32 Although it is unclear why there should be a 
dissociation between IL-6 and TNF-α in our study, soluble 
TNF receptors could possibly account for the normal TNF-α 
expression and elevated IL-6 level in BPD with MDD in the 
present study.
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Figure 1 IL-6 was significantly higher in patients with BPD plus lifetime major 
depressive disorder than in the healthy comparison group (P = 0.0004), but there 
was no significant difference in the concentration of IL-6 between patients with BPD 
plus current major depressive disorder and the healthy comparison group.
Note: error bar: ±standard error of the mean.
Abbreviations: BPD, borderline personality disorder; iL-6, interleukin-6; ns, no 
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In the present study population, BPD with MDD patients 
were more frequently two genotypes of IRS-1 and CYP11B2, 
which are reportedly associated with PCOS in East-Asian 
populations,25,26 compared to the healthy controls (Table 2). 
Although the limitations of this study are largely attributable 
to the nature of association studies, including a small patient 
sample size, and the indices of insulin resistance and endocri-
nal disturbance such as luteinizing hormone/follicle stimulat-
ing hormone ratio and serum androgen were not investigated, 
BPD with MDD was considered to overlap with PCOS in the 
genetic backgrounds of this Japanese population. The most 
important “upstream” driver for reproductive and metabolic 
abnormalities in PCOS is reportedly insulin resistance, and 
thus insulin sensitizing agents, such as thiazolidinediones 
and metformin, are useful for treatment.14 Moreover, an 
elevated serum aldosterone level is reportedly related to 
insulin resistance in women with PCOS.33 Both IRS-1 and 
CYP11B2 were previously described to be associated with 
insulin resistance,34,35 and have been identified in the central 
nervous system (CNS).
Insulin receptor substrate-1 (IRS-1) occupies a key posi-
tion in the insulin signaling pathway. After insulin binding 
to the α-subunit of the insulin receptor, the β-subunit of the 
receptor undergoes autophosphorylation, and in turn, phos-
phorylates other endogenous protein substrates in the insulin 
cascade. IRS-1 is the first direct substrate for the insulin 
receptor kinase.36,37 IRS-1 Gly972Arg is a genetic variant 
of glycine (Gly) to arginine (Arg) change at codon 972 in 
IRS-1. IRS-1 972Arg protein has been reported to act as a 
competitive inhibitor of insulin receptor autophosphorylation 
and to allow IRS-1 to act as an inhibitor of the insulin receptor 
kinase, leading to insulin resistance.38 Actually, carriers of 
this variant have a 25% increased risk for developing Type 2 
diabetes.39 IRS-1 is widely distributed in the CNS, and is 
particularly abundant in the cerebral cortex, the hippocampus, 
many hypothalamic and thalamic nuclei, the basal ganglia, 
the cerebellar cortex, and the brainstem nuclei.40
CYP11B2 -344T/C is a genetic variant in a putative 
binding site for the steroidogenic factor-1 in the 5′ tran-
scriptional regulatory region (-344 thymidine/cytosine). 
Homozygosity for the -344C variant of CYP11B2 has 
been reported to increase the aldosterone-to-renin ratio.41 
  Aldosterone decreases IRS-1 expression and suppresses insu-
lin signaling,42 and clinical reports have indicated that patients 
with primary aldosteronism commonly have impaired 
glucose tolerance.43 It is known that the CNS produces 
aldosterone. CYP11B2 mRNA has been identified in whole 
rat brain homogenates and in the cerebellum, hippocampus, 
hypothalamus, cerebral cortex and amygdala.44 It has also 
been detected in the human brain, although its expression is 
much lower than in the adrenal.45
Accordingly, both the IRS-1 972Arg and CYP11B2 -344C 
alleles are considered to reduce insulin sensitivity in the CNS. 
The brain is an insulin-responsive organ and reduced CNS 
insulin signaling leads to disturbances of fat and glucose 
metabolism.46 Although it remains unclear whether   insulin 
plays a specific neurotransmitter or metabolic role in the 
brain, insulin receptors are widespread throughout the brain 
with dendritic fields receiving rich synaptic input to regulate 
at least energy disposal, fuel metabolism, appetite, auto-
nomic function, cognition, and reproduction.47–49 Insulin can 
down-regulate the function and synthesis of the re-uptake 
transporter for norepinephrine, and can up-regulate those 
for dopamine.50 Therefore, insulin resistance can interfere 
with catecholamine clearance in the CNS, and theoretically 
this could lead to emotional instability. Possible evidence 
for this is given in the next paragraph.
Although little is known about its etiology, many reports 
have demonstrated the hypothalamic origin of PCOS.51–53 
Both IRS-1 and CYP11B2 are distributed in the hypothalamic 
Table 2 Distribution of IRS-1 and SYP11B2 genotypes among 50 patients with borderline personality disorder with comorbid major 
depressive disorder and 100 normal comparison subjects
Genotype BPD with MDD Comparison group ORa (95% CI) P value
n % n %
IRS-1
  gly/gly 44 88 98 98 – –
  gly/Arg 6 12 2 2 6.68 (1.30–34.43) 0.013
CYP11B2
  -344T/T 22 44 49 49 – –
  -344T/c 18 36 44 44 – –
  -344c/c 10 20 7 7 3.32 (1.18–9.35) 0.022
Note: aLogistic regression analysis.
Abbreviations: OR, odds ratio; CI, confidence interval; BPD, borderline personality disorder; MDD, major depressive disorder.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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area and can cause insulin resistance, as described previously. 
Disturbances or functional alterations in the hypothalamus 
and/or its interactions can cause personality changes, lack 
of restraint and inhibitions, and endocrine dysfunction.54 
Several reports have suggested an association between 
insulin resistance and behavioral-pathological problems. 
Amelioration of insulin resistance by arm-cutting behavior 
in depressed adolescents,55 reduced glucose metabolism in 
the temporo-parietal cortices of women with BPD,56 and 
the effectiveness of omega-3 fatty acid treatment for BPD57 
have been reported. We have also reported a case of conduct 
disorder in an adolescent girl who was treated with an insulin 
sensitizing agent, pioglitazone.58 From our present findings 
and previous reports, we suppose that some forms of BPD 
with MDD are a diencephalic disorder54 originating from 
insulin resistance in the CNS.
Insulin sensitizing agents and aldosterone blockers are 
effective for attenuating insulin resistance associated with the 
roles of IRS-1 or CYP11B2. The IRS-1 972Arg variant impairs 
insulin signaling, and treatment with insulin sensitizing agents 
ameliorates this condition. Pioglitazone, a   thiazolidinedione, 
restores normal differentiation of adipocytes and insulin 
signaling defect induced by IRS-1 Gly972Arg variant, and 
the variant modulates the response to metformin therapy in 
women with PCOS.59–61 Moreover, treatment with the selective 
mineralocorticoid receptor antagonist eplerenone has been 
reported to suppress aldosterone and attenuate aldosterone-
induced degeneration of IRS-1.42 Therefore, insulin sensitiz-
ing agents (eg, metformin, thiazolidinediones) and selective 
mineralocorticoid receptor antagonists (eg, eplerenone) might 
have therapeutic potential for individuals with a predisposition 
to some forms of BPD with MDD.
Our study had several limitations. Despite the results 
of genetic analysis seeming to support the involvement of 
IRS-1 and SYP11B2 in BPD with MDD, the possibility of 
false-positive findings cannot be excluded because of the 
small sample size. In addition, metabolic and endocrinal 
disturbances and indices of obesity in the participants were 
not investigated in the present study. Thus, our findings need 
to be confirmed in larger Japanese case control populations 
where metabolic and endocrinal disturbances associated 
with PCOS are investigated. Nevertheless, this is the first 
study to examine the relationship between PCOS associated 
polymorphisms and BPD with MDD.
Conclusion
In conclusion, the predisposition for BPD with MDD is associ-
ated with that for PCOS, in the female Japanese   population. 
An elevated serum IL-6 level is considered to be a possible 
biomarker of BPD with MDD, and to be associated with per-
sonality disorder rather than major depression. The remaining 
challenge is to investigate the hypothalamus-pituitary-ovarian 
axis dysregulation in female patients with BPD with MDD 
and its symptomatic relevance to the menstrual cycle.
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